Experimental drug is first targeted therapy to improve survival in high-risk AML patients

(Dana-Farber Cancer Institute) Midostaurin added to standard chemotherapy is the first targeted treatment to improve survival of a high-risk, genetically defined subgroup of patients with acute myeloid leukemia, reported Dr. Richard Stone, of Dana-Farber Cancer Institute, on behalf of the Alliance for Clinical Trials in Oncology group, in a plenary session at the 57th American Society of Hematology Annual Meeting and Exposition in Orlando.